Skip Ribbon Commands
Skip to main content
Menu
Prof Jenny Low from SGH

Assoc Prof Jenny Low

​MBBS, MRCP (UK), MPH

Senior Consultant

Specialty: Infectious Diseases

Sub-specialties: Infectious Diseases

Clinical Appointments

  • Senior Consultant Infectious Diseases Singapore General HospitalSingapore General Hospital

Profile

Dr Jenny Low is a Senior Consultant with the Department of Infectious Diseases, other than seeing patients her research work includes drug trials for dengue fever.

Education

2011    Certificate of Knowledge, International Society of Travel Medicine
2009    MPH Bloomberg School of Public Health, Johns Hopkins University
2002    MRCP (Internal Medicine), UK (Edinburgh)  
2002    M Med (Internal Medicine) National University of Singapore
1998    MBBS National University of Singapore

Professional Appointments and Committee Memberships

Awards

Publications and Research Trials

  • Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet, Infectious Diseases (In Press) Jenny G Low*, Cynthia Sung*, Limin Wijaya*, Yuan Wei, Abhay P S Rathore, Satoru Watanabe, Boon Hian Tan, Liying Toh, Lian Tee Chua, Yan’an Hou, Angelia Chow, Shiqin Howe, Wing Ki Chan, Kah Hin Tan, Jasmine S Chung, Benjamin P Cherng, David C Lye, Paul A Tambayah,Lee Ching Ng, John Connolly, Martin L Hibberd, Yee Sin Leo, Yin Bun Cheung, Eng Eong Ooi*, Subhash G Vasudevan May 2014 
  • Dengue--old disease, new challenges in an ageing population. Ann Acad Med Singapore. 2013 Aug; 42(8):373-5. Low JG, Ooi EE. Aug 2013 
  • Risk factors for fatality among confirmed adult dengue inpatients in Singapore: a matched case-control study. PLoS One. 2013 Nov 22;8(11):e81060. doi: 10.1371/journal.pone.0081060. eCollection 2013  Thein TL, Leo YS, Fisher DA, Low JG, Oh HM, Gan VC, Wong JG, Lye DC. Nov, 2013 
  • Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012 Jul 31. Watanabe S, Rathore AP, Sung C, Lu F, Khoo YM, Connolly J, Low J, Ooi EE, Lee HS, Vasudevan SG. Jul 2012 
  • Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection PLoS One. 2011;6(12):e29430. Epub 2011 Dec 22.  Balakrishnan T, Bela-Ong DB, Toh YX, Flamand M, Devi S, Koh MB, Hibberd ML, Ooi EE, Low JG, Leo YS, Gu F, Fink K Dec 2011 
  • Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011 Dec; 92(3):453-60  Rathore AP, Paradkar PN, Watanabe S, Tan KH, Sung C, Connolly JE, Low J, Ooi EE, Vasudevan SG.  Dec 2011 
  • The Early Clinical Features of Dengue in Adults: Challenges for Early Clinical Diagnosis PLoS One Neglected Tropical Diseases May 2011 | Volume 5 | Issue 5 | e1191 Jenny G. H. Low, Adrian Ong, Li Kiang Tan, Shera Chaterji, Angelia Chow, Wen Yan Lim3, Koon Wui Lee, Robert Chua, Choon Rong Chua, Sharon W. S. Tan, Yin Bun Cheung3, Martin L. Hibberd, Subhash G. Vasudevan, Lee-Ching Ng, Yee Sin Leo, Eng Eong Ooi May 2011 
  • Genomic epidemiology of a dengue virus epidemic in urban Singapore J Virol. 2009 May;83(9):4163-73. Epub 2009 Feb 11 Ong A, Ooi EE, Vasudevan SG, Hibberd ML. Schreiber MJ, Holmes EC, Ong SH, Soh HS, Liu W, Tanner L, Aw PP, Tan HC, Ng LC, Leo YS, Low JG May 2009 
  • Decision tree algorithms predict the diagnosis and outcome of dengue Fever in the early phase of illness PLoS Negl Trop Dis. 2008 Mar 12;2(3):e196 Tanner L, Schreiber M, Low JG, Ong A, Tolfvenstam T, Lai YL, Ng LC, Leo YS, Thi Puong L, Vasudevan SG, Simmons CP, Hibberd ML, Ooi EE. Mar 2008 
  • Early Dengue Infection and Outcome Study (EDEN) - Study Design and Preliminary Findings. Ann Acad Med Singapore. 2006 Nov;35(11):783 Low JG, Ooi EE, Tolfvenstam T, Leo YS, Hibberd ML, Ng LC, Lai YL, Yap GS, Li CS, Vasudevan SG, Ong A Nov 2006 

Research Trials